Objectives T helper 17 (Th17) cells from patients with early rheumatoid arthritis (RA) induce a proinfl ammatory feedback loop upon RA synovial fi broblast (RASF) interaction, including autocrine interleukin (IL)-17A production. A major challenge in medicine is how to control the pathogenic Th17 cell activity in human infl ammatory autoimmune diseases. The objective of this study was to examine whether tumour necrosis factor (TNF) blockade and/or 1,25-dihydroxyvitamin D 3 (1,25(OH) 2 D 3 ) controls Th17-mediated synovial infl ammation. Methods Peripheral CD4+CD45RO+CCR6+ Th17 cells of patients with early RA, Th17-RASF cocultures and synovial biopsy specimens were cultured with or without 1,25(OH) 2 D 3 and/or TNFα blockade. Intracellular cytokine expression was detected by fl ow cytometry. Cytokine and matrix metalloprotease (MMP) production was determined by ELISA. Results The authors show that the 1,25(OH) 2 D 3 , but not TNFα blockade, signifi cantly suppressed autocrine IL-17A production in Th17-RASF and synovial biopsy cultures. Combining 1,25(OH) 2 D 3 and TNFα blockade had a signifi cant additive effect compared with single treatment in controlling synovial infl ammation, indicated by a further reduction in IL-6, IL-8, MMP-1 and MMP-3 in Th17-RASF cocultures and IL-6 and IL-8 expression in cultures of RA synovial tissue. Conclusions These data show that TNF blockade does not suppress IL-17A and IL-22, which can be overcome by 1,25(OH) 2 D 3 . The combination of neutralising TNF activity and 1,25(OH) 2 D 3 controls human Th17 activity and additively inhibits synovial infl ammation. This indicates more valuable therapeutic potential of activation of Vitamin D receptor signalling over current TNF neutralisation strategies in patients with RA and potentially other Th17-mediated infl ammatory diseases.
The cause of rheumatoid arthritis (RA) is largely unknown. However, substantial evidence has emerged supporting the role of T cells and their cytokines in RA initiation and progression. [1] [2] [3] In particular, interleukin (IL)-17A-producing T helper 17 (Th17) cells are attractive targets for RA treatment. 4 5 Th17 cells are further characterised by IL-17F and IL-22 production and C-C chemokine receptor6 cell-surface expression. [6] [7] [8] The pathogenic role of IL-17A in murine arthritis has been identifi ed. 9 Moreover, mice defi cient in factors underlying Th17 differentiation or function are protected against induction and/or progression of arthritis. 10 11 In the RA-infl amed joint synovium, IL-17A is expressed and IL-17A-producing T cells have been identifi ed. [12] [13] [14] [15] [16] In addition, we have found increased CCR6+ Th17 cell percentages in peripheral blood of treatment-naive patients with early RA. 17 The pathogenic potential of IL-17-producing cells including Th17 cells is further indicated by a decline in disease activity of patients with RA in a clinical anti-IL-17 trial. 18 We recently showed that Th17 cells were potent activators of RA synovial fi broblast (RASF). 17 This Th17-RASF interaction revealed a potential Th17 pathogenic activity as shown by: (1) increased production of IL-6 and IL-8 and matrix metalloprotease (MMP)-1 and MMP-3, mediators of cartilage degradation; (2) induction of autocrine IL-17A production, indicating a Th17-induced proinfl ammatory loop. This loop may be an important pathway in the progression of early infl ammatory arthritis to chronic persistent arthritis. 17 A major challenge in medicine is how to control pathogenic Th17 cell activity in human autoimmune-mediated diseases. Interestingly, the active vitamin D metabolite, 1,25-dihydroxyvitamin D 3 (1,25(OH) 2 D 3 ), has been shown to affect murine Th17 cytokine expression and function. 19 20 The suppressive effects of 1,25(OH) 2 D 3 have been mainly linked to the modulation of functional activities of antigen-presenting cells (APCs). 21 22 Although T cell polarisation can indirectly be affected by 1,25(OH) 2 D 3 -induced altered APC cytokine expression, 23 24 it is becoming clear that T cells, including Th17 cells, are direct 1,25(OH) 2 D 3 targets. [25] [26] [27] In human T cells, 1,25(OH) 2 D 3 suppresses IL-17A and interferon γ (IFNγ) production and stimulates IL-4 and IL-10 production. [28] [29] [30] Moreover, 1,25(OH) 2 D 3 directly reduced the production of the Th17 cytokines, IL-17A, IL-17F and IL-22, by memory T cells of patients with early RA. 27 The proinfl ammatory cytokine, tumour necrosis factor α (TNFα), is a commonly used target for RA treatment. 2 However, 1,25(OH) 2 D 3 had no effect on TNFα production by stimulated peripheral blood mononuclear cells, and only limited inhibitory effects on TNFα production by memory T cells. 27 Since 1,25(OH) 2 D 3 has been shown to inhibit IL-17A production by T cells, we hypothesised that
Flow cytometry antibodies and cell sorting
Monoclonal antibody preparations, intracellular cytokine detection and fl ow cytometry have been described previously. 11 The following monoclonal antibodies were purchased from BD Biosciences (San Diego, California, USA): CD45RO, CCR6, CD4 and IFNγ. IL-22 and IL-17A monoclonal antibodies were from eBioscience (San Diego, California, USA). Samples were acquired on a FACScantoII fl ow cytometer (BD Biosciences) and analysed using FlowJo v7.6 research software (Tree Star Inc, Ashland, Oregon, USA). T cell populations were sorted from peripheral blood mononuclear cells using a FACSAria cell sorter (BD Biosciences).
Cell cultures
T cells (2.5×10 4 ) were cultured for 72 h in Iscove's modifi ed Dulbecco's medium (BioWhittaker, Walkersville, MD, United States), supplemented with 10% fetal calf serum, 100 U/ml penicillin/streptomycin, 2 mM L-glutamine and 50 μM β-mercaptoethanol (Merck, Darmstadt, Germany). Cells were stimulated with soluble αCD3 and αCD28 (0.3 and 0.4 μg/ml, respectively; Sanquin, Amsterdam, The Netherlands) and cultured with or without 100 nM 1,25(OH) 2 In addition, we hypothesised that 1,25(OH) 2 D 3 has an additional role to TNFα blockade in suppressing synovial infl ammation through modulation of Th17 function. These hypotheses were tested using Th17-RASF cocultures from treatment-naïve patients with early RA or RA synovial biopsy cultures from patients with RA undergoing knee joint replacement.
Here we show direct suppressive effects of 1,25(OH) 2 D 3 , but not of TNFα blockade, on IL-17A and IL-22 cytokine expression. Furthermore, the combination of neutralising TNF activity and 1,25(OH) 2 D 3 controls human Th17 activity and additively inhibits synovial infl ammation. These data support the development of a clinical trial combining TNF blockade with VDR activation in RA and other Th17-mediated autoimmune diseases.
METHODS Subjects
In this study, 16 treatment-naive patients with early RA (13 women and three men; mean±SD age 47.8±14.4 years) were studied. All patients fulfi lled the American College of Rheumatology 1987 revised criteria for RA. Blood was obtained at the second visit after informed consent had been obtained. Clinical and laboratory data for the patients can be found in online supplementary table S1. Data from patients with established RA are available on request. This study was embedded in the Rotterdam Early Arthritis Cohort Study and approved by the medical ethics committee of the Erasmus MC Rotterdam. penicillin/streptomycin, in the presence of αCD3/αCD28 and/ or 100 nM 1,25(OH) 2 D 3 and/or 10 μg/ml etanercept.
Cytokine measurements
IL-4, IL-6, IL-8, IL-10 and IFNγ production was determined using ELISA (Invitrogen, Carlsbad, California, USA). IL-17A, IL-22, TNFα, MMP-1 and MMP-3 expression was measured using Duoset ELISA (R&D systems, Minneapolis, Minnesota, USA). ELISA was performed according to the manufacturer's instructions.
Statistical analysis
Differences between experimental groups were tested with a two-sided paired t test or stated otherwise, using Prism software V.5.04 (GraphPad Software Inc. La Jolla, California, USA). p Values <0.05 were considered signifi cant.
RESULTS

1,25(OH) 2 D 3 suppressed Th17-associated cytokine expression by primary memory CCR6+ Th17 cells from patients with early RA
Recently, we showed that 1,25(OH) 2 D 3 suppressed IL-17A and IL-22 expression by CD4+CD45RO+ (memory) T cells from Synovial biopsy specimens (~2 mm) were taken randomly from synovial tissue obtained from patients with established RA after knee joint replacement. Three biopsy samples per group were cultured for 72 h in Dulbecco's modifi ed Eagle's medium supplemented with 10% fetal calf serum and 100 U/ml treatment-naive patients with early RA. 27 By using CCR6 expression, it is possible to sort primary IL-17A-producing memory T cells (CCR6+ Th17) from peripheral blood. 7 17 When these cells of patients with early RA were stimulated in the presence of 1,25(OH) 2 D 3 , a signifi cant reduction was found in the percentage of IL-17A-and IL-22-expressing T cells and in IL-17A and IL-22 protein levels in the supernatant (fi gure 1A,B). In both Th17 and CCR6 memory T cell cultures, 1,25(OH) 2 D 3 reduced the percentage of IFNγ-producing cells and IFNγ protein production (fi gure 1A,B).
1,25(OH) 2 D 3 is known to induce IL-4 production in murine naive T cell cultures 31 and IL-10 production by T cells from patients with multiple sclerosis. 30 In CD4+CD45RO− (naive) T cell, memory CCR6− T cell and memory CCR6+ Th17 cell cultures, 1,25(OH) 2 D 3 was not suffi cient to induce IL-4 production. IL-10 production was not signifi cantly increased by 1,25(OH) 2 From this, we concluded that, in Th17-RASF cocultures, 1,25(OH) 2 D 3 inhibits IL-6, IL-8, IL-17A and MMP-1 expression.
Additive effect of 1,25(OH) 2 D 3 treatment combined with TNF blockade in Th17-RASF cocultures
Recently, we have shown that both IL-17A and TNFα are produced by Th17 cells and that these cytokines are involved in inducing a proinfl ammatory loop in Th17-RASF cocultures. 17 In contrast with 1,25(OH) 2 
DISCUSSION
In this study, we found that 1,25(OH) 2 D 3 , in contrast with TNFα blockade, directly regulates Th17 cytokine expression. Furthermore, 1,25(OH) 2 D 3 in combination with TNFα blockade is essential to fully neutralise pathological Th17 activity in RA synovial infl ammation.
Evidence is accumulating that 1,25(OH) 2 D 3 has a suppressive role in murine experimental autoimmune models 32 33 and in human autoimmune diseases such as RA. [34] [35] [36] [37] However, the mechanism underlying these suppressive effects is not fully elucidated. To analyse the effects of 1,25(OH) 2 D 3 on Th17 cytokine expression and activity, we have used different culturing approaches, including primary Th17 monocultures, Th17-RASF cocultures and synovial biopsy cultures. In all approaches, 1,25(OH) 2 D 3 treatment resulted in suppression of the proinfl ammatory cytokines, IL-17A, IL-22 and IFNγ. Moreover, the 1,25(OH) 2 D 3 effects in synovial tissue cultures not only show the relevance of the Th17-RASF cocultures as a functional T cell test system in RA, but importantly also show the therapeutic potential of 1,25(OH) 2 D 3 /TNF blockade combination as a treatment to control synovial infl ammation in RA, in particular in the presence of IL-17/Th17 activity.
In contrast, IL-4 and IL-10 production was not affected by 1,25(OH)2D3 in Th17 cultures, but was enhanced in Th17-RASF cocultures after 1,25(OH)2D3 treatment. These fi ndings implicate that, in the coculture system, 1,25(OH) 2 D 3 supported Th2 function and/or inhibited factors that can negatively regulate IL-4 expression, such as IFNγ and T-Bet. On the other hand, in this study no effects were found of 1,25(OH) 2 D 3 treatment on TNFα production by Th17-RASF cocultures, whereas, in Th17 monocultures, TNFα production was signifi cantly lower after 1,25(OH) 2 D 3 treatment. This suggests that, besides direct effects of 1,25(OH) 2 D 3 on Th17 cytokines, other factors that are induced in Th17-RASF cocultures and in the infl amed RA synovium are involved in the regulation of IL-4 and TNFα. We found no upregulation of Foxp3 expression in our Th17-RASF cocultures (data not shown), which indicates that the observed suppression is independent of T regulatory cell activity. Moreover, it has to be taken into account that the CCR6+ Th17 population is a heterogeneous population in which cells are present that are negative and positive for the production of either IL-17A or IFNγ or both. The molecular mechanism responsible for the induction of IL-4 by 1,25(OH) 2 D 3 in CCR6+ Th17 cocultures is at present under investigation. group.bmj.com on November 14, 2016 -Published by http://ard.bmj.com/ Downloaded from 1,25(OH) 2 D 3 suppressed Th17 activity as observed by lower IL-6, IL-8 and MMP-1 levels in Th17-RASF cocultures. In an earlier study, we showed that both IL-17A and TNFα blockade are required to neutralise Th17 activity in Th17-RASF cocultures. 17 These cytokines were shown to have synergistic effects on fi broblast activation. 38 39 Further experiments are needed to explain the phenomenon of increased MMP-1 expression by 1,25(OH) 2 D 3 in synovial tissue, focusing on the cellular composition and cellular interaction between cells present in the infl amed synovium.
Progression of joint damage and disease activity has been shown to correlate with the levels of IL-17A and Th17 cells in patients with RA. 16 40 The present study shows that the presence of IL-17A in the synovial biopsy samples has a marked infl uence on the outcome and demonstrates the additional value of the combination of TNFα blocking and 1,25(OH) 2 D 3 treatment compared with TNFα blocking alone. The more IL-17A produced by the synovial biopsy samples after T cell receptor and costimulatory activation, the more valuable the therapeutic potential effect on synovial infl ammation attained by adding 1,25(OH) 2 D 3 to TNFα blocking. This suggests less effective anti-TNF therapy in patients with RA under increased IL-17A levels in these patients. In addition, we recently showed raised levels of memory Th17 cells in treatment-naïve patients with early RA compared with healthy controls. 17 Therefore together these data support the development of a clinical trial combining TNF blockade with VDR activation in patients with RA, in particular at the early stage of the disease.
TNFα blockade is a commonly used treatment in RA. 2 However, a large fraction (~20-40%) of patients do not respond to this therapy. 41 The present study shows that TNFα blockade has no effect on expression of Th17 cytokines such as IL-17A. This may explain why TNFα blockade alone is not effective in all patients with RA and is in line with the suggestion based on preliminary data that TNFα blockade may be less effective in patients with RA who have especially raised levels of IL-17A. 5 Therefore it would be of great interest to investigate whether the group of anti-TNF non-responders has raised levels of Th17 cytokines and/or Th17 cell activity. This study further shows that, for full neutralisation of Th17 activity in RA synovial infl ammation, TNFα blockade needs to be combined with 1,25(OH) 2 D 3 signalling. This underlines the importance of fi nding combinations of therapeutic approaches to improve the effi cacy of current treatment strategies for RA, such as TNFα blockade.
Currently, there is considerable interest in targeting IL-17A or Th17 cells in the treatment of RA and other Th17-mediated disorders. 4 8 In line with this, activation of VDR signalling might be a contending approach. In relation to IL-17A blockade alone, activation of VDR signalling has the advantage that, in addition to IL-17A, other Th17 cytokines, such as IL-17F and IL-22, are downregulated, whereas cytokines such as IL-4 and IL-10 are induced (present study). 27 However, activation of VDR signalling with 1,25(OH) 2 D 3 can have severe side effects such as hypercalcaemia. 42 For this reason, future research should focus on the identifi cation of 1,25(OH) 2 D 3 targets in T cells, and Th17 cells in particular, which may have therapeutic potential for the treatment of RA. Moreover, it should be taken into account that cells of the immune system such as macrophages express the vitamin D-converting enzyme, 1α-hydroxylase, enabling the conversion of 25(OH)D 3 into 1,25(OH) 2 D 3 . 24 43 44 This may imply increased local levels of 1,25(OH) 2 D 3 after administration of 25(OH)D 3 .
In conclusion, this study shows direct suppressive effects of 1,25(OH) 2 D 3 , in contrast with TNFα blockade, on Th17 cytokine expression and activity by Th17 cells from patients with RA. This implies that adding activation of VDR signalling to current TNF blockade therapy may have an additional role in fully neutralising pathogenic Th17 activity in RA and other Th17-mediated autoimmune diseases. Moreover, our data suggest less effective anti-TNF therapy in patients with RA with increased IL-17A levels and provide a rationale for a therapeutic trial combining TNF blockade with VDR activation in patients with RA and potentially also in other Th17-mediated autoimmune disorders.
